- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- PR negative
- ER negative
- PD-L1 negative
- EGFR positive
- BRAF positive
- KRAS positive
- EGFR negative
- p16 positive
- HLA-A positive
- ALK negative
- CD20 positive
- BRCA1 positive
- BRCA2 positive
- IDH positive
- MET positive
- ALK positive
- CD19 positive
- HLA positive
- BRAF negative
- p16 negative
- MYC positive
- HLA negative
- ROS1 negative
- TP53 positive
- HPV positive
- MSI-H positive
- ROS1 positive
- HLA-A negative
- HR positive
- MET negative
- RB1 positive
- dMMR positive
- IDH negative
- NRAS positive
- RET positive
- BRCA positive
- PALB2 positive
- RB1 negative
- PIK3CA positive
- HPV negative
- RAS positive
- BCL2 positive
- FLT3 positive
- MSS positive
- NF1 positive
- CCND1 positive
- KRAS negative
- MMR positive
- NTRK positive
- ATM positive
- BCL6 positive
- BCR-ABL1 positive
- CD30 positive
- PTEN positive
- RET negative
- BRCA1 negative
- CD5 positive
- HbSS positive
- KIT positive
- MGMT negative
- MSH2 positive
- Philadelphia chromosome positive
- RAS negative
- ANA positive
- BRCA2 negative
- MLH1 positive
- MSH6 positive
- MSI negative
- PMS2 positive
- TP53 negative
- anti-dsDNA positive
- dMMR negative
- BRIP1 positive
- CHEK2 positive
- MMR negative
- PD-1 positive
- RAD51 positive
- ctDNA positive
- p53 positive
- ARID1A positive
- CDK12 positive
- MGMT positive
- MSI positive
- NRAS negative
- CLDN18.2 positive
- FANCA positive
- FGFR2 positive
- FLT3 negative
- L858R positive
- MSI-H negative
- NTRK negative
- NTRK1 positive
- RAD51C positive
- CD22 positive
- Ex19del positive
- HRAS positive
- PD-1 negative
- RAD51D positive
- del(17p) positive
- pMMR positive
- BCR-ABL positive
- BRCA negative
- CFTR positive
- FGFR3 positive
- HBV DNA negative
- HBV DNA positive
- HBsAg positive
- HR negative
- HRD positive
- JAK2 positive
- Ki-67 positive
- MSS negative
- NF2 positive
- SMN1 positive
- t(11;14) positive
- ABCA4 positive
- AR positive
- BARD1 positive
- CD123 positive
- CD19 negative
- CD4 count positive
- CD4 positive
- CDK4 positive
- COL7A1 positive
- Complex karyotype positive
- DMD positive
- FGFR positive
- HBsAg negative
- HPV16 positive
- PDGFRA positive
- RAF positive
- RF positive
- SMARCB1 positive
- TERT positive
- t(9;22) positive
- ASXL1 positive
- BAP1 positive
- CD20 negative
- CD3 positive
- CD33 positive
- CDK6 positive
- CHEK1 positive
- FANCL positive
- FRα positive
- HBB positive
- HbSC positive
- MDM2 positive
- MECP2 positive
- MSH6 negative
- MTAP positive
- NBN positive
- NPM1 positive
- PMS2 negative
- PTEN negative
- Ph positive
- Philadelphia chromosome negative
- RAD54L positive
- RB positive
- RUNX1 positive
- SMARCB1 negative
- SMN2 positive
- T790M positive
- TMB positive
- TROP2 positive
- TTR positive
- ZnT8 positive
- anti-Sm positive
- t(11;14)(q13;q32) positive
- AKT negative
- AKT1 positive
- APC positive
- APOL1 positive
- Anti-Smith positive
- CCND1 negative
- CD23 positive
- CD70 positive
- CD8 positive
- CTNNB1 positive
- EBV positive
- EPCAM positive
- EZH2 positive
- FMR1 positive
- FVIII positive
- GLA positive
- GPC3 positive
- GRN positive
- HBcAb positive
- HCV RNA positive
- IA-2 positive
- IA-2A positive
- ICA positive
- IGHV positive
- MLH1 negative
- MRE11 positive
- MSH2 negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- 2 Episodes of Recurrent Clostridium Difficile Infection
- 2 or More Previous Chemotherapies
- >= 2 Bone Metastases (Untreated Lesion)
- ALK TKI Therapy
- ANC >= 1,500/mcL
- AST/ALT =< 3 x ULN
- ATG
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
10018 trials
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing radiation therapy alone to radiation therapy with lymph node dissection in treating breast cancer patients who have already had chemotherapy and surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called adagrasib against an existing chemotherapy drug, docetaxel. It focuses on patients with advanced lung cancer who have a specific genetic mutation (KRAS G12C) and have already had treatment. The new drug aims to block this mutation in cancer cells to stop their growth.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests how well nivolumab works in treating patients with anal cancer after they've received other treatments. Nivolumab may help the body's immune system attack the cancer, and may prevent tumor cells from growing and spreading.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies how well nivolumab works in treating patients with non-small cell lung cancer. Nivolumab is an immunotherapy drug that helps the immune system attack cancer cells. The goal is to see if it can prevent the cancer from coming back. Nivolumab has shown efficacy in treating various malignancies, including non-small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Lymphoma trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying whether adding ibrutinib to chemotherapy before and after stem cell transplant helps the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying afatinib dimaleate with or without cetuximab to treat patients with non-small cell lung cancer that has EGFR mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new chemotherapy treatment for leukemia that includes an immunotherapy drug.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 34 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying a combination of drugs given with or without hormone therapy to see how well they work in treating patients with hormone receptor-positive, HER2-positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Approved for 20 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Multiple Myeloma trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying two different combinations of drugs to treat patients with newly diagnosed multiple myeloma.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if a new drug called TAK-700 helps people with prostate cancer live longer than another drug called bicalutamide when used with ADT.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50